精品国产一区二区三区久久久蜜月-欧美成人黄色-国产片高清在线观看-污网在线观看-亚洲欧美综合视频-中文第一页-97狠狠干-男女日批免费视频-茄子av在线-久久国产精品区-婷婷久久一区

一.產品名稱：

通用名稱：大/小鼠成纖維細胞生長因子23 ELISA試劑盒

英文名稱：Mouse/Rat FGF-23 ELISA Kit

二.Mouse FGF-23 ELISA介紹：

Mouse/Rat FGF-23 ELISA Kit is intended for research use only in the quantitative determination of Mouse FGF-23 levels in serum, plasma or cell culture media. This assay is also useful in the determination of Rat FGF-23 levels.
 

Fibroblast growth factor 23 (FGF-23) is a recently discovered, novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins.

Renal phosphate wasting disorders leading to hypophosphatemia are among the causes of defective mineralization of bone and growth plate development. Autosomal dominant hypophosphatemic rickets (ADHR), a rare genetic disorder, results from one of several different FGF-23 mutations that make the protein resistant to proteolytic cleavage. Furthermore, tumors that cause oncogenic osteomalacia (OOM) have been shown to overexpress FGF-23 mRNA making it likely that elevated concentrations of FGF-23 in the blood are the cause of renal phosphate wasting. Consistent with this conclusion, the administration of recombinant FGF-23 to rodents was shown to increase urinary excretion of phosphate thus leading to hypophosphatemia and osteomalacia/rickets. Recent studies with chronic kidney disease (CKD) patients have shown FGF-23 to be an early predictor of abnormal renal tubular function, bone mineralization, disease progression and over-all mortality risk.

Taken together, all currently available data suggest that the measurement of FGF-23 levels may provide an important diagnostic tool for the evaluation of hypophosphatemic and hyperphosphatemic disorders.
 

如需了解更多產品，請北京科瑞美公司。